The 2025-26 Budget: Medi-Cal Pharmacy Spending

Apr 3, 2025 - What Are Glucagon‑Like Peptide‑1 (GLP‑1) Agonists? GLP ‑1 agonists are a type of drug that help regulate blood sugar, generally by stimulating the release of insulin in the body. Use of these drugs also can result in weight loss among patients.
https://lao.ca.gov/Publications/Report/5026

The 2025-26 California Spending Plan: Health

Oct 16, 2025 - Most notably, the administration plans to end coverage of Glucagon-Like Peptide-1 (GLP-1) agonists used to treat obesity (such as Wegovy). (Medi-Cal will still cover GLP-1s that treat diabetes, such as Ozempic, as required under federal law.)
https://lao.ca.gov/Publications/Report/5075

The 2025-26 Budget: Medi-Cal Pharmacy Spending [Publication Details]

Apr 3, 2025 - This brief provides an overview of pharmacy spending in Medi-Cal, including historical spending trends, assumptions under the 2025-26 Governor’s Budget, and key issues and recommendations for the Legislature.
https://lao.ca.gov/Publications/Detail/5026